AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+14.3%
5Y CAGR+6.0%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+14.3%/yr
vs +3.1%/yr prior
5Y CAGR
+6.0%/yr
Recent acceleration
Acceleration
+11.2pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$64.36B+11.7%
2024$57.64B+58.6%
2023$36.34B-15.7%
2022$43.11B-20.1%
2021$53.95B+12.3%
2020$48.02B+20.7%
2019$39.80B+4.3%
2018$38.17B+9.8%
2017$34.76B+8.1%
2016$32.16B-